Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy
Based on I CAN Phase III trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks - - If approv...